Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus Infections | Zendy

Natalie K. Boyd | Zendy; Cindy Zoellner | Zendy; Mark A. Swancutt | Zendy; Kavita Bhavan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus Infections

Author(s) -

Natalie K. Boyd,

Cindy Zoellner,

Mark A. Swancutt,

Kavita Bhavan

Publication year - 2012

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00700-12

Subject(s) - voriconazole , pharmacokinetics , pharmacology , therapeutic drug monitoring , aspergillus , medicine , drug , omeprazole , toxicity , antifungal , biology , microbiology and biotechnology , dermatology

Voriconazole is the preferred antifungal agent forAspergillus infections. Therapeutic drug monitoring is recommended to achieve target concentrations and prevent toxicity. However, variable pharmacokinetics, cytochrome P450 polymorphisms, and extensive drug-drug interactions can contribute to subtherapeutic concentrations. We report a voriconazole “boosting” effect of omeprazole to achieve target concentrations for the treatment ofAspergillus in a patient who had persistently subtherapeutic trough concentrations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research